<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426099</url>
  </required_header>
  <id_info>
    <org_study_id>CNO22011</org_study_id>
    <nct_id>NCT02426099</nct_id>
  </id_info>
  <brief_title>Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension</brief_title>
  <acronym>SPIRY</acronym>
  <official_title>Prevalence and Treatment of Resistant Hypertension in Diabetic Patients in Yaounde</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sobngwi Eugene</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Yaounde 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yaounde Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a four-week randomized controlled single blinded trial of subjects presenting with
      resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly
      assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to
      routine intensification of antihypertensive regimen , all added to previous regimen with
      unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four
      following add-on therapy initiation. The primary outcome is change in office and
      self-measurement blood pressure recorded at each visit, and secondary outcomes are variations
      in serum potassium, sodium, and creatinine levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (Blood pressure reduction)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Blood pressure reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potassium (Change in serum potassium)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine (Change in serum creatinine)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum creatinine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hypertension, Resistant to Conventional Therapy</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Low dose Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add-on low dose 25 mg Spironolactone to current hypertension treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine intensification of anti hypertensive treatment based on existing guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose spironolactone</intervention_name>
    <description>4-week add-on low dose spironolactone in resistant hypertension</description>
    <arm_group_label>Low dose Spironolactone</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine intensification of antihypertensive treatment</intervention_name>
    <description>4-week guidelines oriented intensification of antihypertensive treatment</description>
    <arm_group_label>Routine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resistant hypertension

          -  Diabetes mellitus

        Exclusion Criteria:

          -  T2DM with overt acute/chronic complications,

          -  serum potassium ≥ 5.5 mmol/l,

          -  estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet
             in Renal Disease formula ≤ 30 ml/min/1.73m² of body weight,

          -  absolute contraindication to any of the drug regimen of the trial,

          -  and current aldosterone antagonist treatment or cessation within the last 15 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Mbanya, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Yaounde 1</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Obesity Centre, Yaounde Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yaounde Central Hospital</investigator_affiliation>
    <investigator_full_name>Sobngwi Eugene</investigator_full_name>
    <investigator_title>Professor and Consultant Physician</investigator_title>
  </responsible_party>
  <keyword>Resistant hypertension</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>African</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

